The Law Offices of Frank R. Cruz Announces Investigation of Lexicon Pharmaceuticals, Inc. (LXRX) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) (NASDAQ: LXRX) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On February 28, 2022, Lexicon issued a press release announcing the voluntary withdrawal of the Company’s New Drug Application for its glucose regulation drug, sotagliflozin, in order to correct a technical issue with the submission that had been recently identified by the Company.

On this news, Lexicon’s stock price fell $0.78, or 27.37%, to close at $2.07 per share on February 28, 2022, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Lexicon securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [e-mail], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220308006337/en/